APLT - Applied Therapeutics

-

$undefined

N/A

(N/A)

Applied Therapeutics NasdaqGM:APLT Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG. It develops AT-001 that is in phase 3 clinical trials to treat diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy; and AT-003, which is in preclinical studies for the treatment diabetic retinopathy. The company has exclusive license and supply agreement with Mercury Pharma Group Limited to commercialize drug products containing AT-007. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.

Location: 545 Fifth Avenue, New York, NY, 10017, United States | Website: https://www.appliedtherapeutics.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

2.976M

Cash

50.76M

Avg Qtr Burn

-23.51M

Short % of Float

16.74%

Insider Ownership

4.90%

Institutional Own.

83.05%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Govorestat (AT-007) Details
Galactosemia, Rare diseases, Rare genetic disease

NDA

Resubmission

Govorestat (AT-007) Details
Sorbitol dehydrogenase deficiency

NDA

Submission

Caficrestat (AT-001) Details
Hemophilia, Genetic disorder, Diabetic cardiomyopathy

Phase 3

Update

Govorestat (AT-007) Details
Phosphomannomutase 2 deficiency , Congenital disorder of glycosylation

Phase 2

Update

AT-003 Details
Diabetic retinopathy

Phase 1

Update

AT-104 Details
Leukemia, B-cell acute lymphoblastic leukemia, T-cell lymphoma

Failed

Discontinued